Top Markets
#1 DogBull DogBull +55.29%
#2 Wrapped STX (Velar) Wrapped STX (Velar) +31.82%
#3 Siren Siren +30.75%
#4 Purr Purr +19.29%
#5 DigiByte DigiByte +17.88%
#6 OriginTrail OriginTrail +16.28%
#7 龙虾 (Lobster) 龙虾 (Lobster) +12.34%
#8 Ethena Staked ENA Ethena Staked ENA +11.62%
#9 Wrapped XPL Wrapped XPL +10.75%
#10 Plasma Plasma +10.71%
Coin of the day
DogBull DogBull
Настройки
Язык
Pусский
Валюта
USD
Тема
Adocia S.A. Adocia S.A.

Adocia S.A.

ADOC
Ранг среди акций #21864
Adocia S.A. is a clinical-stage biotechnology firm that specializes in... Adocia S.A. is a clinical-stage biotechnology firm that specializes in developing enhanced formulations of existing therapeutic proteins and peptides, primarily targeting diabetes and other metabolic disorders. The company leverages its unique BioChaperone technological platform, specifically designed to boost the performance of these therapeutic proteins. Its robust clinical pipeline showcases several advanced insulin formulations, including BioChaperone Lispro U100 and U200, which are ultra-rapid-acting versions of insulin lispro. Other key candidates are BioChaperone Combo, a blend of long-acting insulin glargine and rapid-acting insulin lispro; BioChaperone LisPram, which pairs prandial insulin with pramlintide; and BioChaperone Glucagon, an aqueous human glucagon formulation for managing hypoglycemia. M1Pram, a derivative combining insulin glargine and pramlintide, is also under clinical investigation. In its earlier preclinical development phases, Adocia is advancing bi-hormonal products such as BioChaperone AsPram, a combination of rapid insulin aspart and pramlintide, and BioChaperone Glargine Liraglutidea, a fixed-dose pairing of insulin glargine with a GLP-1 receptor analogue. The preclinical portfolio also extends to multihormonal therapies for obesity, featuring BioChaperone GluExe (glucagon and exenatide), PramExe (pramlintide and exenatide), and BioChaperone PramGluExe, a triple combination of pramlintide, glucagon, and exenatide. Adocia has established a strategic partnership with Tonghua Dongbao Pharmaceutical Co., Ltd. to facilitate the development and commercialization of BioChaperone Lispro and BioChaperone Combo in China, as well as selected markets in Asia and the Middle East. The company was founded in 2005 and is headquartered in Lyon, France.
Цена акции
$4.95
Последняя синхронизация: 2026-08-21
Рыночная капитализация
$98.96M
Изменение (1 день)
1.16%
Изменение (1 год)
-52.59%
Страна
FR
Торговля Adocia S.A. (ADOC)

Категория

Healthcare
История цены акций Adocia S.A. (ADOC)
Наивысшая цена закрытия: $4.94 2026-08-01

Наименьшая цена закрытия: $20.35 2012-02-01
История цены акций Adocia S.A. с 2012 по 2026
Годовая динамика цены акций
Год Результативность
2026 (TTM) -10.19%
2025 18.14%
2024 -31.11%
2023 200.94%
2022 -63.48%
2021 -9.28%
2020 4.72%
2019 -33.48%
2018 -15.89%
2017 -69.48%
2016 -30.64%
2015 95.38%
2014 420.10%
2013 -37.65%
2012 0.00%
Цена акций похожих компаний или конкурентов
Компания Цена акций Изменение 1г% Страна
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $547.71 38.62%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $1.04K 58.06%
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $145.75 437.43%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $118.70 -15.60%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 $770.19 8.98%
CH